- Atara Biotherapeutics ( NASDAQ: ATRA ) on Tuesday said it had entered into a $31M royalty interest financing agreement with investment firm HealthCare Royalty (HCRx) for its drug Ebvallo.
- Shares of ATRA rose 11.4% to $3.90 after hours.
- The deal with HCRx comes a day after ATRA and commercialization partner Pierre Fabre's Ebvolla got European approval as the first therapy for adults and children with Epstein?Barr virus positive post?transplant lymphoproliferative disease (EBV+ PTLD).
- EBV+ PTLD is a potentially fatal complication that can occur after solid organ or bone marrow transplantation.
- The royalty interest financing agreement is for Ebvallo in Europe and other territories covered by Atara's ( ATRA ) commercialization agreement with Pierre Fabre.
- As per the terms of the deal, ATRA will get a $31M upfront payment from HCRx.
- In exchange, HCRx will receive rights to specified royalties and milestones under the Pierre Fabre commercialization agreement for Europe and other territories.
For further details see:
Atara Biotherapeutics, HealthCare Royalty ink $31M royalty interest financing deal